To develop a haemophilia-specific questionnaire exploring Quality of Life (QoL) of four age groups: adult (18-36 years), adolescent (12-17 years), children (7-11 years), and young children (3-7 years).
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Mapi Values, LYON, France; 2 CHU Bicetre, Kremlin Bicetre, France; 3 CHU Timone, Marseille, France; 4 CTS, Le Chesnay, France; 5 CHU Hotel Dieu, Nantes, France; 6 CHU Hopital Trouseau, Tours, France OBJECTIVES: To develop a haemophilia-specific questionnaire exploring Quality of Life (QoL) of four age groups: adult (18-36 years), adolescent (12-17 years), children (7-11 years) , and young children (3-7 years). METHODS: The questionnaire was developed in French following a literature review and in depth interviews among 3 men suffering from severe haemophilia, 3 mothers of haemophilia children and 5 clinical experts (2 haematologists, 1 paediatrician, 1 nurse and 1 psychologist). RESULTS: An adult version of the questionnaire was first developed using patient's verbatim. It contained 89 questions and covered the following 7 quality of life domains: Haemophilia and its treatment, Daily life, School, Professional life, Leisure activities and sports, Family and friends, Emotional well-being and Future perspective. Three other versions of the questionnaire were developed simultaneously based on the adult version: 77item adolescent questionnaire, 22-item children questionnaire and 45-item parent of children questionnaire. All domains were covered in all versions, except for professional life. All age-group versions are self-administered including children from 7 to 11 years old. In addition parents fill in the 45-item questionnaire for 3-11 agegroups. Content validity of the questionnaires was submitted to a Scientific committee for revision and approval. The questionnaire is currently being evaluated in a French cross-sectional pilot study including 54 severe haemophilia A patients. The objectives are to describe QoL items among different age groups, assess the acceptability and the relevance of the questionnaire and perform item-reduction. CONCLUSION: The reduced QoL questionnaire will be available to the scientific community soon for further psychometric analysis. The Haemophilia age-group QoL questionnaire offers the unique opportunity to assess haemophilia patients' QoL from early childhood to adult life. This study was supported by a grant from Baxter.
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PHL12
MORE PRECISE DOSING INCREMENTS OF HUMAN GROWTH HORMONE DELIVERY SYSTEMS LEAD TO COST SAVINGS IN THE UK SETTING
Lammert M, Roze S, Lurati FM,Valentine WJ, Palmer AJ CORE Center for Outcomes Research, Binningen, Basel, Switzerland OBJECTIVES: Human growth hormone (hGH) treatment is potentially expensive, and improvements in dosing accuracy through more precise delivery systems may lead to reductions in costs due to a minimization of wastage. To test this hypothesis, we assessed potential cost savings in the treatment of childhood growth hormone deficiency (GHD) and small for gestational age (SGA) due to differences in the precision of dosing of hGH delivery systems. METHODS: Three delivery systems with differing dose increment size were compared (Norditropin NordiFlex with dosing increments of 0.025 mg versus Genotropin Pen and Humatrope Pen both with 0.1 mg dosing increments). The recommended daily dose of hGH for each indication for 1 kg body weight intervals was combined with costs per mg hGH (taken from published UK sources) to calculate annual costs of hGH treatment for GHD and SGA patients. The calculations were based on the assumption that patients received the required daily dose as a minimum or the lowest possible injectable dose above the required daily dose. RESULTS: Due to more precise incremental dose delivery, using Norditropin NordiFlex versus the two other comparators was found to save an average of 6.2% of the annual hGH dose. This translated into annual drug cost savings of £254.32 and £179.53 per patient compared to Genotropin Pen and Humatrope Pen respectively. In patients with lower body weight, where smaller dosing increments were more critical to accurate dosing, even greater savings of up to 10% were found. These results were robust in all body weight categories and in both GHD and SGA. CONCLUSIONS: More precise dosing with the Norditropin NordiFlex delivery system compared to Genotropin Pen and Humatrope Pen led to cost savings in the UK setting in patients with GHD and SGA.
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THE USE OF A CONDITION-SPECIFIC QUALITY OF LIFE MEASURE (QUALITY OF LIFE-ASSESSMENT FOR GROWTH HORMONE DEFICIENCY IN ADULTS) IN A GENERAL POPULATION
Kind P 1 , Hennessy S 1 , Koltowska M 2 1 University of York, York, England; 2 KIGS/KIMS Outcomes Research, Pharmacia AB, Stockholm, Sweden Generic measures of health-related quality of life (HrQoL) are designed for use in a wide range of therapeutic settings whereas condition-specific measures have a much narrower focus. The performance of the latter in general population settings is largely unknown. OBJEC-TIVES: 1) To demonstrate the differential health status of individuals with a specific condition and hence its health burden; 2) to test the discriminatory power of a condition-specific measure of HrQoL and; 3) to develop normative reference values of QoL-AGHDA. METHODS:
